Why Patients Switch to 1.7 mg Wegovy for Better Value
Switching to 1.7 mg Wegovy: The Strategic Transition
The decision to switch from Mounjaro or Ozempic to 1.7 mg Wegovy often centres on cost optimisation without compromising clinical effectiveness. At this advanced dose level—weeks 13-16 of your escalation—you're experiencing the full appetite-suppressing benefits of GLP-1 receptor agonists alongside your dietary and exercise routine. Many patients find that switching to Wegovy at the 1.7 mg stage provides substantial monthly savings whilst maintaining therapeutic momentum. Your prescriber can guide the transition, often suggesting approximate dose equivalences to ensure continuity of treatment.
EverydayMeds stocks both medications, eliminating the complexity of finding new pharmacy providers during your switch. This seamless approach means your prescription history, delivery preferences, and clinical notes remain centralised. Our returning customers benefit from the DOSE25 discount code, ensuring the most competitive pricing for your 1.7 mg Wegovy continues beyond the initial switch.
1.7 mg Wegovy Pricing: Transparent Savings Breakdown
Our 1.7 mg Wegovy pens cost £139.99 after applying your applicable discount code at checkout. New patients use FIRST40 whilst returning customers apply DOSE25 to achieve this competitive pricing. This represents significant monthly savings compared to equivalent Mounjaro doses, which typically cost £180-200 per pen through other providers. The Elevate Duo bundle combines 1.7 mg with 2.4 mg maintenance dosing for £369.99, providing a complete transition pathway to your long-term treatment dose.
For patients requiring extended time at the 1.7 mg level, our Consistency 1.7mg bundle delivers two pens for £309.99. This option suits individuals who prefer gradual dose escalation or those whose prescriber recommends additional weeks at this level before progressing to maintenance. All bundles include temperature-controlled next-day delivery, ensuring your prescription-only medicine maintains optimal efficacy throughout the switching process.
Clinical Evidence Supporting 1.7 mg Wegovy Effectiveness
The STEP clinical trial programme demonstrated that patients taking Wegovy alongside diet and exercise achieved meaningful weight management outcomes. In STEP 1, participants experienced approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo. The 1.7 mg dose represents a crucial escalation point where many patients begin experiencing the full therapeutic benefits of semaglutide.
Recent SELECT cardiovascular outcomes data showed a 20% reduction in major cardiovascular events (hazard ratio 0.80) in patients taking Wegovy, as reported by Wilding et al., NEJM, 2021. This evidence supports switching decisions based on both weight management goals and broader health considerations, particularly for patients with cardiovascular risk factors.
How 1.7 mg Wegovy Works in Your System
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone. At the 1.7 mg dose, you're receiving a therapeutic level that significantly reduces appetite whilst promoting satiety after smaller meals. The medication works on brain appetite centres, potentially reducing food cravings and supporting your dietary modifications. Unlike rapid-acting medications, Wegovy's once-weekly dosing provides consistent appetite regulation throughout the seven-day period. This sustained approach supports the lifestyle changes essential for long-term weight management success.
Ordering Your 1.7 mg Wegovy: Simple Process
Our switching process begins with a 3-minute online clinical assessment covering your current GLP-1 medication, dosing history, and transition goals. Our qualified prescribers review applications within 3 working days (express 24-hour service available), considering your switching rationale and ensuring clinical appropriateness. Once approved, your 1.7 mg Wegovy ships via next-day cold-chain delivery, maintaining the 2-8°C temperature requirements. Your prescription-only medicine arrives in discrete packaging with full storage instructions and injection guidance. Customer support remains available throughout the switching period to address any transition concerns.
Storage and Practical Advantages of 1.7 mg Wegovy
Wegovy's FlexTouch pen system offers superior room temperature stability compared to Mounjaro—6 weeks versus 21 days once removed from refrigeration. This advantage proves particularly valuable for frequent travelers or those with variable schedules. The 1.7 mg dose requires weekly injections, typically administered on the same day each week for optimal consistency. Store unopened pens in your refrigerator at 2-8°C, switching to room temperature storage (below 30°C) once you begin using each pen. The pen design includes dose confirmation features, ensuring accurate administration during your escalation phase before reaching 2.4 mg maintenance dosing.
1.7 mg Wegovy Switch Strategy: Timing Your Transition
The optimal switching point to 1.7 mg Wegovy often occurs when patients have established tolerance to GLP-1 medications but seek cost optimization before reaching maintenance dosing. Many prescribers recommend switching between equivalent doses rather than during escalation periods, ensuring treatment continuity. Your current Mounjaro or diabetes-focused Ozempic dose may translate to specific Wegovy equivalents, though prescriber guidance remains essential for safe transitions.
Patients switching at the 1.7 mg level benefit from maintaining therapeutic momentum whilst accessing Wegovy's superior room temperature stability and competitive pricing. EverydayMeds' clinical team, operating under GPhC registration #9012878, can coordinate with your existing prescriber to ensure seamless transition documentation and appropriate monitoring throughout the switching process.
Complete Your Switch: Secure Your 1.7 mg Wegovy Supply
Ready to switch to 1.7 mg Wegovy and start saving on your weight management journey? Our clinical assessment takes just 3 minutes, with most prescriptions approved within our standard timeframes. New customers apply code FIRST40 at checkout, whilst returning patients use DOSE25 to access the £139.99 pricing for 1.7 mg pens. Consider our Elevate Duo bundle for seamless progression to maintenance dosing, or select individual pens based on your switching timeline. Visit our weight loss collection to begin your clinical assessment and secure next-day delivery of your prescription-only medicine. Trust EverydayMeds' expertise in GLP-1 medication transitions—your health journey deserves professional support.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
